Christiana Brenin

This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.

This prospective, single-arm observational trial examines whether aromatase inhibitor therapy in postmenopausal women with HR-positive breast cancer adversely affects cardiorespiratory fitness, skeletal muscle function, and immunosenescence.